<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-11010-2014064 - 2S2UI</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Eliminating IP barriers to treatment in Malaysia</narrative>
  </title>
  <description type="4">
   <narrative xml:lang="EN">As of December 2013, there were 100,000 PLHIV in Malaysia. The number receiving anto-retroviral therapy (ART) rose to approximately 14,784 people, which is 45% of treatment coverage. The MoH estimates that it currently costs between US $4 million and US $7 million to provide ART per year. The MoH does provide second-line ART free of charge at some government hospitals. However, not all of those facilities have proved willing and able to participate in this initiative. Some, for instance, have yet to enroll enough patients to meet their target. Currently, the Malaysian government is having an intensive negotiation in U.S-led Trans Pacific Partnership Agreement (TPPA) and E.U-Malaysia FTA which will undermine access to affordable medicine.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">As the only registered organization in Malaysia consisting of PLHIV, Positive Malaysian Treatment Access &amp; Advocacy Group (MTAAG+) advocates for affordable medicines for all in need of those drugs. To sustain and increase the number of people living with HIV on treatment, stricter criteria for granting patents and a better  use of compulsory licenses are needed in Malaysia. In this project MTAAG+ will focus on training, community mobilization and advocacy on TRIPS flexibilities and harmful intellectual property provisions in trade agreements. As a country with a small population but several generic manufacturers that can meet international standards, the long term goal for MTAAG+ and other partners is to have Malaysia as a potential exporter of generic medicines.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">Main outcomes:
# Documentation, research and analysis of existing Malaysian patent law conducted to provide inputs for the national patent law review and to prevent intellectual property provisions in trade agreements that reduce TRIPS flexibilities for public health.
# Patent status for essential medicines documented and dossiers prepared as the basis for patent challenges and review
# Increased capacity of the PLHIV community regarding TRIPS flexibilities for public health.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN"></narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">MTAAG+</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2014-12-31" type="1"></activity-date>
  <activity-date iso-date="2018-12-31" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <recipient-country code="MY" percentage="100"></recipient-country>
  <location>
   <name>
    <narrative xml:lang="EN">Kuala Lumpur</narrative>
   </name>
  </location>
  <sector code="15160" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Eliminating IP barriers to treatment in Malaysia Human rights</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2014-12-31"></period-start>
   <period-end iso-date="2018-12-31"></period-end>
   <value currency="EUR" value-date="2014-12-31">118670</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">31645</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">31645</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-03-27"></transaction-date>
   <value currency="EUR" value-date="2016-03-27">15823</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-03-30"></transaction-date>
   <value currency="EUR" value-date="2016-03-30">15823</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-09-27"></transaction-date>
   <value currency="EUR" value-date="2016-09-27">15823</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-09-27"></transaction-date>
   <value currency="EUR" value-date="2016-09-27">15823</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-03-26"></transaction-date>
   <value currency="EUR" value-date="2017-03-26">20000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-03-27"></transaction-date>
   <value currency="EUR" value-date="2017-03-27">20000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-09-26"></transaction-date>
   <value currency="EUR" value-date="2017-09-26">20000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-09-27"></transaction-date>
   <value currency="EUR" value-date="2017-09-27">20000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-06-26"></transaction-date>
   <value currency="EUR" value-date="2019-06-26">2383</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-06-27"></transaction-date>
   <value currency="EUR" value-date="2019-06-27">2383</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014064</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-02-21"></transaction-date>
   <value currency="EUR" value-date="2018-02-21">12379</value>
   <description>
    <narrative xml:lang="EN">Extra payment.The final &#x20AC;3.000 will be paid upon approval of the final report</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-02-21"></transaction-date>
   <value currency="EUR" value-date="2018-02-21">12379</value>
   <description>
    <narrative xml:lang="EN">Extra payment.The final &#x20AC;3.000 will be paid upon approval of the final report</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">MTAAG+</narrative>
   </receiver-org>
  </transaction>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">A.  Increased understanding of how policy research output can be translated into implementation with ability to make demands in the Patents Act and IP chapter of the Trans Pacific Partnership Agreement (TPPA) and Malaysia-EU FTA</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">A1a  Policy research and analysis combined with technical analysis; documentation</narrative>
   </description>
   <indicator measure="2">
    <title>
     <narrative xml:lang="EN">A2. Updated yearly data gathering status of selected ARVs &amp; DAAs are available.</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="1"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="100"></target>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="100"></target>
    </period>
   </indicator>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">A1  Five identified issues and recommendations from the results of the research incorporated into the revised patent law and IP chapter in the TPPA and Malaysia-EU FTA</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="2"></actual>
    </period>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="2"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="5"></target>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="5"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">B.  Evidenced-based arguments to prevent &quot;evergreening&quot; and propose India Patent Act  Section 3(d) for the Malaysian Patents Act to strengthen TRIPs flexibilities.</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">B2b.  Ensure availability of legal experts to take action on the dossiers</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">B2  At least one patent challenge filed in Year 2</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="1"></target>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="1"></target>
    </period>
   </indicator>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">B1  Five dossiers of  selected ARVs &amp; DAAs for potential challenge at the Malaysian Intellectual Property Office (number of challenges to be filed will be determined in Year 2 after the Year 1 research)</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="3"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="5"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">C.  PLHIV are empowered to move forward on action plans.</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">C2a. Facilitate training of trainers among the target PLHIV support group.</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">C2  270 peer educators has knowledge to advocate in 9 training sessions (3 sessions per year).</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="85"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="270"></target>
    </period>
   </indicator>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">C1  5,000 informed members of target group reached through social media by end of Project period.</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="1888"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="5000"></target>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="5000"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">D. Momentum and impact created by PLHIV &amp; PLHCV demands and message reached to higher level.</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">D2a.  Organise 3 public meetings or rallies:
(i) to increase awareness of IP barriers during key meeting dates of trade agreements negotiations
(ii) to increase awareness of access to treatment on World Hepatitis Day.</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">D2.  10 journalists (print and audio/visual media) sensitized on IP and public health</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="2"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="10"></target>
    </period>
   </indicator>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">D1.  Core group of 15 committed members of parliament and state legislators, policy makers, public health professionals</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="10"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="15"></target>
    </period>
   </indicator>
  </result>
 </iati-activity>
</iati-activities>
